ESPR Dec 2023 2.500 call
| Previous close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.1500 |
| Ask | 0.5500 |
| Strike | 2.50 |
| Expiry date | 2023-12-15 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 412 |
GlobeNewswireEsperion Announces Adjournment of 2023 Annual Meeting of Stockholders
ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 13, 2023 (the “Proxy Statement”). The Annual Meeting, originally scheduled to be held on May 25, 2023 at 8:00 a.m. Eastern Time, and subsequen
- GlobeNewswire
Esperion to Participate in Jefferies Healthcare Conference
ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th, 2023 at 9:00 AM ET. The Esperion management team will also be available to host 1 on 1 investor meetings. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion webs
- GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 9, 2023, the Company granted 13 new employees 71,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement materi
ZacksEsperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up
Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.
ZacksEsperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Esperion Reports First Quarter 2023 Financial Results
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with $56 Million in Financing – – Global Regulatory Filings Anticipated in 1H 2023 – – Entered into Commercial Partnership with Currax Pharmaceuticals – ANN ARBOR, Mich., May 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2023 a
- GlobeNewswire
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
– Gibson Dunn Files Amended Complaint with Powerful New Evidence –ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”) and filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300 million milestone payment to Esperion
- GlobeNewswire
Esperion to Participate in JMP Securities Life Sciences Conference
ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Securities Life Sciences Conference on Monday, May 15th, 2023 at 2:00 PM ET. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approxim
- GlobeNewswire
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
ANN ARBOR, Mich., April 27, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America Securities 2023 Health Care Conference on Thursday, May 11th, 2023, at 11:40 AM PDT. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be availa
ZacksEsperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Following the release, company management will host a webcast at 8:00 a.m. ET to discuss financial results and business progress. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. Already registered? Access with your PIN
- GlobeNewswire
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales Team – ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of Currax’s 72 sales representatives to co-promote NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
- GlobeNewswire
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available ap
ZacksEsperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent in lieu thereof) wa
- GlobeNewswire
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock in a registered direct offering priced at-the-market under
Simply Wall St.Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers
The latest analyst coverage could presage a bad day for Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), with the analysts...
ZacksEsperion (ESPR) Plummets 54% Over Milestone Payment Row
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
ZacksEsperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.
- GlobeNewswire
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – – Following the “Lower Is Better For Longer” Approach to Lipid Management, the Recently Published Paper Provides Evidence-Based Guidance on Using Bempedoic Acid in Atherosclerotic Cardiovascular Disease (ASCVD), Heterozygous Familial Hypercholesterolemia (HeFH) and Statin Intolerance – – Based on This Guidan
- GlobeNewswire
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin– NEXLETOL Significantly Reduced Risk of Major Adverse Cardiovascular Events (MACE-4) and (MACE-3) by 13% (P=0.004) and 15% (P=0.006), Respectively, and Significantly Reduced Risk of Myocardial Infarction by 23% (P=0.002) and Coronary Revascularization by 19% (P=0.001) – – CLEAR Outcomes Demonstrated Superior Cardiovascular Outcomes Benefits Compared with
- GlobeNewswire
Esperion Launches New Scientific Website
Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion’s Landmark CLEAR Outcomes Study, Company Pipeline and MoreANN ARBOR, Mich., Feb. 24, 2023 (GLOBE NEWSWIRE) -- With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared towards the scientific and medical communities, delivers information about Esperion’s CLEAR program and the clinical trials com
- GlobeNewswire
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
ANN ARBOR, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Sheldon Koenig, president and chief executive officer, will present at Cowen’s 43rd annual Health Care Conference on Wednesday, March 8th, 2023 at 9:10 AM ET. To register for the live webcast, follow this link. A live webcast can be accessed on the investors and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call a
- Simply Wall St.
Need To Know: The Consensus Just Cut Its Esperion Therapeutics, Inc. (NASDAQ:ESPR) Estimates For 2023
One thing we could say about the analysts on Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) - they aren't optimistic...
ZacksEsperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
